Hvis dere er interessert i Moderna anbefaler jeg å høre på intervjuet med CEO Stephane Bancel i the long run podcasten.
1 Like
Litt saksing fra : https://investors.modernatx.com/news-releases/news-release-details/moderna-host-science-day-may-7-2019-and-report-first-quarter
Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019 –
–with a focus on the Company’s newest advances from its commitment to basic and applied sciences. Moderna will also host a tour of the Norwood manufacturing facility in the afternoon.–
–
—Both events will be webcast live under “Events & Presentations” in the Investors section of the Moderna website at https://investors.modernatx.com/. The archived webcasts will be available on Moderna’s website approximately two hours after each event and will be available for 30 days following the events.
1 Like
2 Likes
AstraZeneca dukker opp her. PCI Biotech har forskningssamarbeid med AstraZeneca siden 2015. Kan det være at det benyttes PCI Biotech teknologi?
Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. (NASDAQ: AZN) and Merck, Inc. (NASDAQ: MRK), as well as the Defense Advanced Research Projects Agency (NASDAQ: DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS)
1 Like
Lurer på om vi har snakket litt om dette selskapet i andre tråder, i usa har det jo vært en liten snakkis:
2 Likes
2 Likes
https://www.niaid.nih.gov/news-events/atlanta-site-added-nih-clinical-trial-vaccine-covid-19
Emory University in Atlanta will begin enrolling healthy adult volunteers ages 18 to 55 years in a Phase 1 clinical trial of an investigational vaccine designed to prevent coronavirus disease 2019 (COVID-19). The trial, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, began last week at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. KPWHRI and Emory are part of NIAID’s Infectious Diseases Clinical Research Consortium.
The trial aims to enroll a total of 45 participants across the two sites. NIAID scientists and clinicians have been closely monitoring the outbreak of COVID-19 in Washington and throughout the United States. They decided to expand the trial to another geographic area to ensure efficient enrollment.
Evan Anderson, M.D., associate professor of pediatrics and medicine, and Nadine Rouphael, M.D., associate professor of medicine, will lead the study at Emory. Participants will receive two shots of the experimental vaccine approximately one month apart and will be followed for approximately one year
3 Likes
8 Likes
Moderna said that mRNA-1273 was generally found to be safe and well tolerated, with a safety profile consistent with that seen in prior Moderna infectious disease vaccine clinical studies. The company expects the Phase 3 trial to start in July, subject to the finalization of the clinical trial protocol.
"The Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July and, if successful, file a BLA,” said Stéphane Bancel, CEO at Moderna. “We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2.”
An experimental vaccine from the U.S. biotechnology company Moderna Inc. showed signs that it can create an immune-system response to fend off the new coronavirus, offering tentative hopes in the global effort to combat the pandemic.
The results are just a sample from the small, first study designed to look at the safety of the shot in human volunteers, and should be viewed with caution. But they showed no major safety worries, a key first hurdle since a vaccine would be given to millions of otherwise healthy people.
“This is a very good sign that we make an antibody that can stop the virus from replicating,” Moderna Chief Executive Officer Stephane Bancel said in an interview. The data “couldn’t have been better,” he said. The company is moving ahead with plans for a larger test to pick a dose of the vaccine and further study its effectiveness, as well as a phase 3 test with many thousands of patients.
2 Likes
Kom tilfeldigvis over denne da jeg satt og leste om Moderna, er det noe hold i disse påstandene?
(Regner med alle som er interessert i Biotek har sett dokumentaren om Theranos 
)
1 Like
Moderna har faktiske produkter som de tester i mennesker som er antatt å kunne “disrupte” legemiddelindustrien(mRNA) og er priset deretter. Theranos var svindel fra ende til annen og hadde aldri et produkt. Shortselgere finner på mye rart og mange selskaper som er pre-kommersielle blir mål for slike.
1 Like
To ord: Peer Review
Man kan si hva man vil om børsprisingen av Moderna, men noen scam frykter jeg ikke at de er.
De har hatt mange publications oppetter, hadde de vært fraudulent hadde dette kommet frem for lenge siden, gitt hvor mye cred det hadde vært for en gravende journalist å ta ned “det neste Theranos”.
https://www.modernatx.com/newsroom/publications
Edit:
Artikkelen din er fra 2016 ffs, de har jo hatt IPO siden den gang.
2 Likes
Hvordan kommer du over dette? En artikkel på et random sted som er 5 år gammel. Oppsøker du det bevisst eller hvordan skjer det? 
Siste artikkel fra artikkelforfatter er denne best-mothers-day-gifts-2020-spa-wine-jewelry-skincare
1 Like
Haha, ja, så det var en gammel artikkel. Ble nevnt i kommentarfeltet på en Twitterkonto - denne:
1 Like
4 Likes
